FAPI-PET in Cardiovascular Disease
- PMID: 38519308
- DOI: 10.1053/j.semnuclmed.2024.02.006
FAPI-PET in Cardiovascular Disease
Abstract
PET probes targeting fibroblasts are frequently used for varying applications in oncology. In recent years, the clinical spectrum has been expanded towards cardiovascular medicine, e.g., after myocardial infarction, in aortic stenosis or as a non-invasive read-out of atherosclerosis. We herein provide a brief overview of the current status of this PET radiotracer in the context of cardiovascular disease, including translational and clinical evidence. In addition, we will also briefly discuss future applications, e.g., the use of fibroblast-targeting PET to investigate bilateral organ function along the cardiorenal axis.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rudolf A. Werner reports a relationship with German Research Foundation that includes: funding grants. Rudolf A. Werner reports a relationship with Novartis that includes: consulting or advisory. Rudolf A. Werner reports a relationship with PentixaPharm that includes: consulting or advisory and travel reimbursement. Takahiro Higuchi reports a relationship with German Research Foundation that includes: funding grants. Takahiro Higuchi reports a relationship with Okayama University that includes: funding grants. Takahiro Higuchi reports a relationship with Japan Society for the Promotion of Science that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources